

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:


**Listing of Claims:**

1. (Currently amended): A compound of Formula I:


A-B

~~its prodrug forms~~, or pharmaceutically acceptable salts thereof, wherein

A represents ~~a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure substituted with R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>20</sup>~~



B represents




X and Y independently at each occurrence are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and


Z represents C or N; provided that, (i) when Z represents N, R<sup>7</sup> represents H or C(=NH)NH<sub>2</sub>;

R<sup>1</sup> represents OH, halogen, COOH, COO-C<sub>1-4</sub> alkyl, O-(CH<sub>2</sub>)<sub>0-1</sub>-Ph, N(R<sup>10</sup>)<sub>2</sub>, CH<sub>2</sub>OR<sup>10</sup>, C<sub>1-6</sub> halogenated alkyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-CO-N(R<sup>10</sup>)<sub>2</sub>, SC<sub>1-4</sub> alkyl, NHSO<sub>2</sub>C<sub>1-4</sub>alkyl, SO<sub>2</sub>-OH, O-SO<sub>2</sub>-OH, O-SO<sub>2</sub>-O-C<sub>1-4</sub> alkyl, OP(O)(OH)<sub>2</sub>, or ~~OP(O)(OH)OC<sub>1-4</sub> alkyl~~ OP(O)(OH)OC<sub>1-4</sub> alkyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> independently at each ~~occurrence~~ occurrence represent H, SH, OR<sup>10</sup>, halogen, COOR<sup>10</sup>, CONR<sup>11</sup>R<sup>12</sup>, optionally substituted aryl, optionally substituted heterocyclyl, C<sub>4-14</sub> cycloalkyl-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl aryl, optionally substituted C<sub>1-14</sub> straight chain, branched or cyclo alkyl, O-(CH<sub>2</sub>)<sub>2-6</sub>-NR<sup>10</sup>-(CH<sub>2</sub>)<sub>0-3</sub>-R<sup>24</sup>, NR<sup>10</sup>R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>33</sup>R<sup>34</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-COOR<sup>33</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-CO-het, O-(CH<sub>2</sub>)<sub>1-2</sub>-NH-CO-aryl, O-(CH<sub>2</sub>)<sub>1-2</sub>-NR<sup>10</sup>-CO-NR<sup>10</sup>R<sup>33</sup>, O-(CH<sub>2</sub>)<sub>0-2</sub>-C(O)-NR<sup>33</sup>R<sup>34</sup>, O-(CH<sub>2</sub>)<sub>1-4</sub>-COOR<sup>10</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-het-R<sup>32</sup>, O-optionally substituted cycloalkyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-COO-*t*-butyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>R<sup>33</sup>, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-C(O)-C<sub>0-3</sub>-alkyl-optionally substituted aryl, O-substituted cycloalkyl, O-(CH<sub>2</sub>)<sub>0-6</sub>-optionally substituted aryl, (CH<sub>2</sub>)<sub>1-4</sub>-NH-C(O)O-(CH<sub>2</sub>)<sub>1-4</sub>-PhR<sup>13</sup>R<sup>14</sup>, NO<sub>2</sub>, O-(CH<sub>2</sub>)<sub>0-4</sub>-C(O)-NH-tetrahydro carboline, NR<sup>10</sup>R<sup>28</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-optionally substituted het, CH<sub>2</sub>COOCH<sub>3</sub>, CH=CH-COOCH<sub>3</sub>, 5-amidino benzimidazole,



alternatively R<sup>2</sup> and R<sup>3</sup> taken together form



$R^6$  and  $R^9$  independently at each ~~occurrence~~ occurrence represents H, halogen, cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  halogenated alkyl,  $NO_2$ , O-aryl or  $OR^{11}$ ;

$R^7$  and  $R^8$  independently at each ~~occurrence~~ occurrence represent OH,  $CF_3$ , H,  $NO_2$ ,  $C_{1-4}$  alkyl,  $OC_{1-4}$  alkyl, ~~or~~ O-aryl, halogen, or cyano, or a basic group selected from guanidino,  $C(=NH)N(R^{10})_2$ ,  $C(=NH)-NH-NH_2$ ,  $C(=O)NH_2$ , 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that ~~only one~~, but not both, of  $R^7$  and  $R^8$  represents a basic group;

$R^{10}$  independently at each ~~occurrence~~ occurrence represents H,  $(CH_2)_{0-2}$ -aryl,  $C_{1-4}$  halo alkyl, or  $C_{1-14}$  straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two  $R^{10}$  groups, the atom along with the  $R^{10}$  groups can form a five to 10 membered ring structure;

$R^{11}$  and  $R^{12}$  independently at each ~~occurrence~~ occurrence represent H or  $C_{1-4}$  alkyl;

$R^{20}$  represents  $R^{24}$ ,  $C_{1-4}$ -alkyl,  $(CH_2)_{1-3}$ -biphenyl,  $(CH_2)_{1-4}$ -Ph- $N(SO_2-C_{1-2}$ -alkyl) $_2$ ,  $(CH_2)_{1-4}$ -NH-C(O)- $R^{24}$ ,  $(CH_2)_{1-4}$ -NH-SO $_2$ - $R^{24}$ , halogen, COOR $^{10}$ ,  $(CH_2)_{1-4}$ -Ph- $N(SO_2-C_{1-2}$ -alkyl),  $(CH_2)_{1-4}$ -NR $^{10}$ -C(O)- $R^{24}$ ,  $(CH_2)_{1-4}$ -NR $^{10}$ -SO $_2$ - $R^{24}$ ,  $(CH_2)_{1-4}$ -het,  $(CH_2)_{1-4}$ -CON( $R^{10}$ ) $_2$ ,  $(CH_2)_{1-4}$ -N( $R^{10}$ )-C(O)-NR $^{10}$  $R^{24}$ ,  $(CH_2)_{1-4}$ -N( $R^{10}$ )-C(S)-NR $^{10}$  $R^{24}$ , or  $(CH_2)_{1-3}$ -COOH;

$R^{24}$  represents  $R^{10}$ ,  $(CH_2)_{1-4}$ -optionally substituted aryl,  $(CH_2)_{0-4}$ OR $^{10}$ , CO- $(CH_2)_{1-2}$ -N( $R^{10}$ ) $_2$ , CO $(CH_2)_{1-4}$ -OR $^{10}$ ,  $(CH_2)_{1-4}$ -COOR $^{10}$ ,  $(CH_2)_{0-4}$ -N( $R^{10}$ ) $_2$ , SO $_2$ R $^{10}$ , COR $^{10}$ , CON( $R^{10}$ ) $_2$ ,  $(CH_2)_{0-4}$ -aryl-COOR $^{10}$ ,  $(CH_2)_{0-4}$ -aryl-N( $R^{10}$ ) $_2$ , or  $(CH_2)_{1-4}$ -het-aryl;

$R^{28}$  represents  $(CH_2)_{1-2}$ -Ph-O- $(CH_2)_{0-2}$ -het- $R^{30}$ , C(O)-het,  $CH_2$ -Ph- $CH_2$ -het- $(R^{30})_{1-3}$ ;  $(CH_2)_{1-4}$ -cyclohexyl- $R^{31}$ ,  $CH_2$ -Ph-O-Ph- $(R^{30})_{1-2}$ ,  $CH_2$ -( $CH_2OH$ )-het- $R^{30}$ ,  $CH_2$ -Ph-O-cycloalkyl- $R^{31}$ ,  $CH_2$ -het-C(O)- $CH_2$ -het- $R^{30}$ , or  $CH_2$ -Ph-O- $(CH_2)$ -O-het- $R^{30}$ ;


$R^{30}$  represents  $SO_2N(R^{10})_2$ , H, NHOH, amidino, or  $C(=NH)CH_3$ ;

$R^{31}$  represents  $R^{30}$ , amino-amidino,  $NH-C(=NH)CH_3$  or  $R^{10}$ ;

$R^{32}$  represents H, C(O)- $CH_2$ - $NH_2$ , or C(O)- $CH(CH(CH_3)_2)$ - $NH_2$ ;

$R^{33}$  and  $R^{34}$  independently at each ~~occurrence~~ occurrence represent  $R^{10}$ ,  $(CH_2)_{0-4}$ -Ar, optionally substituted aryl,  $(CH_2)_{0-4}$  optionally substituted heteroaryl,  $(CH_2)_{1-4}$ -CN,  $(CH_2)_{1-4}$ - $N(R^{10})_2$ ,  $(CH_2)_{1-4}$ -OH,  $(CH_2)_{1-4}$ - $SO_2-N(R^{10})_2$ ; alternatively;

$R^{33}$  and  $R^{34}$  along with the nitrogen atom that they are attached form ~~to form~~ a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



$R^{35}$  represents  $R^{10}$ ,  $SO_2-R^{10}$ ,  $COR^{10}$ , or  $CONHR^{10}$ ;

E represents a bond,  $S(O)_{0-2}$ , O or  $NR^{10}$ ;

$W_1$ ,  $W_2$ ,  $W_3$  and  $W_4$  independently represent C or N; and

$Q$ ,  $Q^1$ ,  $Q^2$ ,  $Q^3$ ,  $L^1$ ,  $L^2$ ,  $L^3$  and  $L^4$  independently at each ~~occurrence~~ occurrence represent N-natural or unnatural amino acid side chain,  $CHR^{10}$ , O, NH,  $S(O)_{0-2}$ ,  $N-C(O)-NHR^{10}$ ,  $SO_2-N(R^{10})_2$ ,  $N-C(O)-NH-(CH_2)_{1-4}-R^{26}$ ,  $NR^{10}$ , N-heteroaryl,  $N-C(=NH)-NHR^{10}$ , or  $N-C(=NH)C_{1-4}$  alkyl;


$R^{26}$  represents OH,  $NH_2$ , or SH;

provided that, (i) when  $R^1 = OH$ ;  $R^7 =$  amidine;  $R^2$ ,  $R^6$ ,  $R^8$ ,  $R^9$ , and  $R^{20}$  each represent H; and  $R^3$ ,  $R^4$ ,  $R^5$  are independently chosen from H,  $CH_3$ , and halogen, then only one of  $R^3$ ,  $R^4$ , and  $R^5$  represents H; (ii) when  $R^1 = OH$ ;  $R^7 =$  amidine;  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^{20}$  each represent

H; and  $R^6, R^8, R^9$  are independently chosen from H,  $CH_3$ , and halogen, then only one of  $R^6, R^8$ , and  $R^9$  represents H; (iii) at least two of  $W_1, W_2, W_3$  and  $W_4$  represent C and at least one of  $W_1, W_2, W_3$  and  $W_4$  represent N; and (iv) when  $R^1 = OH$ ;  $R^7 =$  amidine; and  $R^2, R^3, R^4, R^5, R^6, R^8$ , and  $R^9$ , represent H,  $R^{20}$  cannot be  $CH_3$ .

2. (Canceled)

3. (Currently amended): A compound of Claim 2 1 wherein  
~~A represents~~



$R^1$  represents OH, O-Ph, COOH or  $P(O)(OH)_2$ ;

$R^7$  represents H, ~~Br~~,  $CONH_2$ , CN,  $C(=NH)-NH-NH_2$ ,  $NH-C(=NH)-NH_2$  or  $C(=NH)-NH_2$ ;


$R^{20}$  represents H,  $C_{1-2}$  alkyl,  $(CH_2)_{1-4}$ -optionally substituted aryl,  $(CH_2)_{1-4}$ -het;  $(CH_2)_{1-4}-N(R^{10})_2$ ,  $(CH_2)_{1-4}-CON(R^{10})_2$ ,  $(CH_2)_{1-4}-NR^{10}-C(O)-R^{24}$ ,  $(CH_2)_{1-4}-NR^{10}-SO_2-R^{24}$ , or  $(CH_2)_{1-3}-COOH$ ;

~~X and Y independently at each occurrence are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH; and~~


Z represents C or N;

provided that, (i) when Z represents N,  $R^7$  represents H or  $C(=NH)NH_2$ .

4. (Currently amended): A compound of claim 3 wherein  
A represents



B represents



X and Y represent N; and

R<sup>7</sup> represents -CONH<sub>2</sub> or C(=NH)-NH<sub>2</sub>.

5. (Currently amended): A compound of claim 4 wherein

R<sup>1</sup> represents OH, -COOH, and or O-P(O)(OH)<sub>2</sub>;


R<sup>2</sup> and R<sup>3</sup> independently represent halogen, H, C<sub>1-4</sub> alkyl, Ph, toluyl, OH, ~~O-(CH<sub>2</sub>)<sub>1-3</sub>-C(O)-~~  
NH-(CH<sub>2</sub>)<sub>1-2</sub>-CN O-(CH<sub>2</sub>)<sub>1-2</sub>-C(O)-NH-(CH<sub>2</sub>)<sub>1-2</sub>-CN, O-(CH<sub>2</sub>)<sub>1-3</sub>-Ph-*p*-OCH<sub>3</sub>, O-CH<sub>2</sub>-C(O)-  
NH-(CH<sub>2</sub>)<sub>1-2</sub>-CH-(CH<sub>3</sub>)<sub>2</sub>, O-CH<sub>2</sub>-C(O)-NH-(CH<sub>2</sub>)-Ph, O-CH<sub>2</sub>-C(O)-NH-(CH<sub>2</sub>)-Ph-*p*CH<sub>3</sub>, O-  
C<sub>1-3</sub> alkyl, O-(CH<sub>2</sub>)<sub>0-2</sub>-Ph-R<sup>10</sup>, O-CH<sub>2</sub>-C(O)-NH-(CH<sub>2</sub>)<sub>2</sub>-H, Ph-C<sub>1-3</sub> alkyl, Ph-N(R<sup>10</sup>)<sub>2</sub>, O-  
(CH<sub>2</sub>)<sub>1-3</sub>-het, O-(CH<sub>2</sub>)<sub>1-3</sub>-Ph-halo, O-(CH<sub>2</sub>)<sub>1-3</sub>-NHCO<sub>2</sub>Ph-R<sup>10</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-NHCO-(CH<sub>2</sub>)<sub>0-2</sub>-Ph,  
O-CH<sub>2</sub>-C(O)-NH-CH<sub>2</sub>-COO-C(CH<sub>3</sub>)<sub>3</sub>, O-(CH<sub>2</sub>)<sub>2</sub>-NHC(O)-CH<sub>2</sub>-NH<sub>2</sub>, -OPh, O-(CH<sub>2</sub>)<sub>1-3</sub>-NH-  
het, O-(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-pyridyl, O-(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-NH-benzyl, O-(CH<sub>2</sub>)<sub>2</sub>-cyclohexyl, O-  
(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-(CH<sub>2</sub>)<sub>2</sub>-CONH<sub>2</sub>, O-(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-CH<sub>2</sub>-OCH<sub>3</sub>, thiophene, pyridyl or O-  
(CH<sub>2</sub>)<sub>2</sub>-pyridyl;

alternatively R<sup>2</sup> and R<sup>3</sup> taken together form

Appl. No. 09/868,276

Amdt. dated December 18, 2003

Reply to Office Action of June 24, 2003



$R^4$  represents halogen, H,  $\text{NO}_2$ ,  $\text{C}_{1-2}$ -alkyl,  $\text{CH=CH-COOCH}_3$ ,  $\text{NHSO}_2\text{C}_{1-2}$  alkyl,  $\text{NHCO-het}$ ,  $(\text{CH}_2)_{1-3}\text{-COOR}^{10}$ ,  $(\text{CH}_2)_{1-3}\text{-CONH-(CH}_2)_{1-3}\text{-pyridyl}$ , or  $(\text{CH}_2)_{1-3}\text{-CONH-(CH}_2)_{1-3}\text{-dichlorophenyl}$ ;

$R^5$  represents H;

$R^6$  represents H;

$R^7$  represents  $\text{C(=NH)-NH}_2$  or  $\text{NH(=NH)NH}_2$ ;

$R^8$  represents H, halogen,  $\text{OR}^{10}$ ,  $\text{CF}_3$ , or  $\text{C(=NH)-NH}_2$ ;

$R^9$  represents H or halogen; and

$R^{20}$  represents H.

6. (Canceled)


7. (Currently amended): A compound of claim ~~6~~ 5 wherein

$R^1$  represents OH, or COOH;

$R^2$  represents H, halogen, OH, phenyl,  $\text{O-(CH}_2)_{1-3}\text{-Ph}$ , imidazolyl, 5-amidino benzimidazolyl,  $\text{O-(CH}_2)_{1-2}\text{-C(O)-NH-C}_{1-6}$  alkyl, or  $\text{O-CH}_2\text{-C(O)-NH-CH}_2\text{-Ph}$ ;

$R^3$  represents H,  $\text{O-CH}_2\text{-COOH}$ ,  $\text{O-CH}_2\text{-C(O)O-C}_2\text{H}_5$ ,  $\text{O-CH}_2\text{-C(O)-NH-(CH}_2)_{1-4}\text{-aryl}$ ,  $\text{O-(CH}_2)_{1-4}\text{-NH-C(O)-naphthyl}$ ,  $\text{CONH}_2$ ,  $\text{O-(CH}_2)_{1-2}\text{-C(O)N(R}^{10})\text{-(CH}_2)_{1-3}\text{-Ph-R}^{13}\text{R}^{14}$ ,  $\text{O-CH}_2\text{-C(O)-N(R}^{10})\text{-CH}_2\text{-piperanyl}$ ,  $\text{O-CH}_2\text{-C(O)-NH-CH}_2\text{-indoyl}$ ,  $(\text{CH}_2)_{0-4}\text{-aryl}$ ,

Appl. No. 09/868,276  
 Amdt. dated December 18, 2003  
 Reply to Office Action of June 24, 2003




R<sup>4</sup> represents H, -CH<sub>3</sub>, halogen, -OCH<sub>3</sub>, -(CH<sub>2</sub>)<sub>1-2</sub>COOR<sup>10</sup>, -COOH, -NO<sub>2</sub>, -OH, aryl,



Appl. No. 09/868,276

Amdt. dated December 18, 2003

Reply to Office Action of June 24, 2003



$R^5$  represents H;

$R^6$  represents H;

$R^7$  represents H, halogen,  $-C(O)-NH_2$ ,  $-C(=NH)-NH_2$ ;


$R^8$  represents H, Cl, F, OH or  $OCH_3$ ;

$R^9$  represents H; and

$R^{13}$  and  $R^{14}$  independently at each ~~occurrence~~ occurrence represents H, halogen,  $-OC_{1-2}$  alkyl,

~~-OH~~,  $-CF_3$ , or  $-C_{1-4}$  alkyl; and

$R^{15}$  represents H,



R<sup>20</sup> represents H or -CH<sub>2</sub>-Ph.

8. (Currently amended): A compound of claim 2, wherein the compound is selected from

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-phenethyl-propionamide;

3-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenyl]-N-(2,3-dichloro-benzyl)-propionamide;

2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(2,3-dichloro-benzyl)-acetamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-[2-(2,4-dichloro-phenyl)-ethyl]-propionamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(2-pyridin-2-yl-ethyl)-propionamide;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-N-(3-phenyl-propyl)-propionamide;

2-[4-(6-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-naphthalen-1-ylmethyl-acetamide;

2-(3'-Amino-5-chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

3-[3-Bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-propionic acid;

2-(3,5-Bis-hydroperoxy-2-hydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine;

2-[4-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-N-(3-chloro-benzyl)-acetamide;

N-Benzyl-3-[3-bromo-5-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-4-hydroxy-phenyl]-propionamide;

2-(3,5-Dibromo-2,4-dihydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine;

2-(2-Hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

2-(5-Chloro-2-hydroxy-biphenyl-3-yl)-3H-benzoimidazole-5-carboxamidine;

Appl. No. 09/868,276  
Amdt. dated December 18, 2003  
Reply to Office Action of June 24, 2003

2-(2-Hydroxy-3-phenethyloxy-phenyl)-3H-benzoimidazole-5-carboxamidine;  
N-(3-Bromo-benzyl)-2-[4-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-  
acetamide;  
2-{3-[1-(3-Amino-propionyl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-  
benzoimidazole-5-carboxamidine;  
2-(5-Chloro-2-hydroxy-3-pyridin-3-yl-phenyl)-1H-benzoimidazole-5-carboxamidine;  
2-[3-(5-Carbamimidoyl-1H-benzoimidazol-2-yl)-2-hydroxy-phenyl]-3,4,6,7-tetrahydro-  
imidazo[4,5-c]pyridine-5-carboxamidine;  
2-[3-(1-Aminoacetyl-pyrrolidin-2-ylmethoxy)-2-hydroxy-phenyl]-3H-benzoimidazole-5-  
carboxamidine; and  
2-(2-Hydroxy-3-phenoxy-phenyl)-3H-benzoimidazole-5-carboxamidine;  
2-[2-Hydroxy-3-(1-methyl-1H-benzoimidazol-2-yl)-phenyl]-1H-benzoimidazole-5-  
carboxamidine;  
2-[3-(1-Aminoacetyl-piperidin-3-ylmethoxy)-2-hydroxy-phenyl]-1H-benzoimidazole-5-  
carboxamidine;  
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-1H-  
benzoimidazole-5-carboxamidine;  
2-[2-Hydroxy-3-(1-hydroxyacetyl-pyrrolidin-2-ylmethoxy)-phenyl]-1H-benzoimidazole-5-  
carboxamidine;  
2-(2-Hydroxy-5-iodo-3-methoxy-phenyl)-1H-benzoimidazole-5-carboxamidine;  
2-{3-[1-(2-Amino-3-methyl-butyryl)-pyrrolidin-2-ylmethoxy]-2-hydroxy-phenyl}-3H-  
benzoimidazole-5-carboxamidine;  
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-benzylamino}-phenyl)-3H-  
benzoimidazole-5-carboxamidine; compound with methane;  
2-(2-Hydroxy-5-{4-[1-(1-imino-ethyl)-piperidin-3-ylmethoxy]-benzylamino}-phenyl)-3H-  
benzoimidazole-5-carboxamidine;  
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3H-benzoimidazole-5-carboxamidine;

3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid;

3-[2,6-Dibromo-4-(6-carbamimidoyl-1H-benzoimidazol-2-yl)-3-hydroxy-phenoxy]-propionic acid ethyl ester; and

2-[3-Bromo-2-hydroxy-5-(3-methoxy-but-3-enyl)-phenyl]-3H-benzoimidazole-5-carboxamidine;

or a stereoisomer or pharmaceutically acceptable salt form thereof.

9. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.


10. (Canceled)

11. (Currently amended): A method for treating or preventing a ~~thromboembolic disorder~~ arterial thromboembolism, comprising administering to a patient in need thereof a therapeutically effective amount of a compound ~~according to Claim 2~~ having the formula:


A-B

or pharmaceutically acceptable salts thereof, wherein


A represents



or



B represents




X and Y independently at each occurrence are selected from NH, N, C, or CH, such that at least one of X and Y always represents N or NH ; and


Z represents C or N; provided that, (i) when Z represents N, R<sup>7</sup> represents H or C(=NH)NH<sub>2</sub>;

R<sup>1</sup> represents OH, halogen, COOH, COO-C<sub>1-4</sub> alkyl, O-(CH<sub>2</sub>)<sub>0-1</sub>-Ph, N(R<sup>10</sup>)<sub>2</sub>, CH<sub>2</sub>OR<sup>10</sup>, C<sub>1-6</sub> halogenated alkyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-CO-N(R<sup>10</sup>)<sub>2</sub>, SC<sub>1-4</sub> alkyl, NHSO<sub>2</sub>C<sub>1-4</sub>alkyl, SO<sub>2</sub>-OH, O-SO<sub>2</sub>-OH, O-SO<sub>2</sub>-O-C<sub>1-4</sub> alkyl, OP(O)(OH)<sub>2</sub>, or OP(O)(OH)OC<sub>1-4</sub> alkyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> independently at each occurrence represent H, SH, OR<sup>10</sup>, halogen, COOR<sup>10</sup>, CONR<sup>11</sup>R<sup>12</sup>, optionally substituted aryl, optionally substituted heterocyclyl, C<sub>4-14</sub> cycloalkyl-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl aryl, optionally substituted C<sub>1-14</sub> straight chain, branched or cyclo alkyl, O-(CH<sub>2</sub>)<sub>2-6</sub>-NR<sup>10</sup>-(CH<sub>2</sub>)<sub>0-3</sub>-R<sup>24</sup>, NR<sup>10</sup>R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>33</sup>R<sup>34</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-COOR<sup>33</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-CO-het, O-(CH<sub>2</sub>)<sub>1-2</sub>-NH-CO-aryl, O-(CH<sub>2</sub>)<sub>1-2</sub>-NR<sup>10</sup>-CO-NR<sup>10</sup>R<sup>33</sup>, O-(CH<sub>2</sub>)<sub>0-2</sub>-C(O)-NR<sup>33</sup>R<sup>34</sup>, O-(CH<sub>2</sub>)<sub>1-4</sub>-COOR<sup>10</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-het-R<sup>32</sup>, O-optionally substituted cycloalkyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-COO-*t*-butyl, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>R<sup>33</sup>, O-(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-C(O)-C<sub>0-3</sub>-alkyl-optionally substituted aryl, O-substituted cycloalkyl, O-(CH<sub>2</sub>)<sub>0-6</sub>-optionally substituted aryl, (CH<sub>2</sub>)<sub>1-4</sub>-NH-C(O)O-(CH<sub>2</sub>)<sub>1-4</sub>-PhR<sup>13</sup>R<sup>14</sup>, NO<sub>2</sub>, O-(CH<sub>2</sub>)<sub>0-4</sub>-C(O)-NH-tetrahydro carboline, NR<sup>10</sup>R<sup>28</sup>, O-(CH<sub>2</sub>)<sub>1-3</sub>-optionally substituted het, CH<sub>2</sub>COOCH<sub>3</sub>, CH=CH-COOCH<sub>3</sub>, 5-amidino benzimidazole,



alternatively R<sup>2</sup> and R<sup>3</sup> taken together form



R<sup>6</sup> and R<sup>9</sup> independently at each occurrence represents H, halogen, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> halogenated alkyl, NO<sub>2</sub>, O-aryl or OR<sup>11</sup>;

R<sup>7</sup> and R<sup>8</sup> independently at each occurrence represent OH, CF<sub>3</sub>, H, NO<sub>2</sub>, C<sub>1-4</sub> alkyl, OC<sub>1-4</sub> alkyl, O-aryl, halogen, or cyano, or a basic group selected from guanidino, C(=NH)N(R<sup>10</sup>)<sub>2</sub>, C(=NH)-NH-NH<sub>2</sub>, C(=O)NH<sub>2</sub>, 2-imidazoline, N-amidinomorpholine, N-amidino piperidine, 4-hydroxy-N-amidino piperidine, N-amidino pyrrolidine, tetrahydro pyrimidine, and thiazolidin-3-yl-methylideneamine; with the proviso that one, but not both, of R<sup>7</sup> and R<sup>8</sup> represents a basic group;

R<sup>10</sup> independently at each occurrence represents H, (CH<sub>2</sub>)<sub>0-2</sub>-aryl, C<sub>1-4</sub> halo alkyl, or C<sub>1-14</sub> straight chain, branched or cyclo alkyl, and alternatively, when one atom is substituted with two R<sup>10</sup> groups, the atom along with the R<sup>10</sup> groups can form a five to 10 membered ring structure;

R<sup>11</sup> and R<sup>12</sup> independently at each occurrence represent H or C<sub>1-4</sub> alkyl;

R<sup>20</sup> represents R<sup>24</sup>, C<sub>1-4</sub>-alkyl, (CH<sub>2</sub>)<sub>1-3</sub>-biphenyl, (CH<sub>2</sub>)<sub>1-4</sub>-Ph-N(SO<sub>2</sub>-C<sub>1-2</sub>-alkyl)<sub>2</sub>, (CH<sub>2</sub>)<sub>1-4</sub>-NH-C(O)-R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-NH-SO<sub>2</sub>-R<sup>24</sup>, halogen, COOR<sup>10</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-Ph-N(SO<sub>2</sub>-C<sub>1-2</sub>-alkyl), (CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-C(O)-R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-SO<sub>2</sub>-R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-het, (CH<sub>2</sub>)<sub>1-4</sub>-CON(R<sup>10</sup>)<sub>2</sub>, (CH<sub>2</sub>)<sub>1-4</sub>-N(R<sup>10</sup>)-C(O)-NR<sup>10</sup>R<sup>24</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-N(R<sup>10</sup>)-C(S)-NR<sup>10</sup>R<sup>24</sup>, or (CH<sub>2</sub>)<sub>1-3</sub>-COOH;

R<sup>24</sup> represents R<sup>10</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-optionally substituted aryl, (CH<sub>2</sub>)<sub>0-4</sub>OR<sup>10</sup>, CO-(CH<sub>2</sub>)<sub>1-2</sub>-N(R<sup>10</sup>)<sub>2</sub>, CO(CH<sub>2</sub>)<sub>1-4</sub>-OR<sup>10</sup>, (CH<sub>2</sub>)<sub>1-4</sub>-COOR<sup>10</sup>, (CH<sub>2</sub>)<sub>0-4</sub>-N(R<sup>10</sup>)<sub>2</sub>, SO<sub>2</sub>R<sup>10</sup>, COR<sup>10</sup>, CON(R<sup>10</sup>)<sub>2</sub>, (CH<sub>2</sub>)<sub>0-4</sub>-aryl-COOR<sup>10</sup>, (CH<sub>2</sub>)<sub>0-4</sub>-aryl-N(R<sup>10</sup>)<sub>2</sub>, or (CH<sub>2</sub>)<sub>1-4</sub>-het-aryl;

R<sup>28</sup> represents (CH<sub>2</sub>)<sub>1-2</sub>-Ph-O-(CH<sub>2</sub>)<sub>0-2</sub>-het-R<sup>30</sup>, C(O)-het, CH<sub>2</sub>-Ph-CH<sub>2</sub>-het-(R<sup>30</sup>)<sub>1-3</sub>; (CH<sub>2</sub>)<sub>1-4</sub>-cyclohexyl-R<sup>31</sup>, CH<sub>2</sub>-Ph-O-Ph-(R<sup>30</sup>)<sub>1-2</sub>, CH<sub>2</sub>-(CH<sub>2</sub>OH)-het-R<sup>30</sup>, CH<sub>2</sub>-Ph-O-cycloalkyl-R<sup>31</sup>, CH<sub>2</sub>-het-C(O)-CH<sub>2</sub>-het-R<sup>30</sup>, or CH<sub>2</sub>-Ph-O-(CH<sub>2</sub>)-O-het-R<sup>30</sup>;


R<sup>30</sup> represents SO<sub>2</sub>N(R<sup>10</sup>)<sub>2</sub>, H, NHOH, amidino, or C(=NH)CH<sub>3</sub>;

R<sup>31</sup> represents R<sup>30</sup>, amino-amidino, NH-C(=NH)CH<sub>3</sub> or R<sup>10</sup>;

R<sup>32</sup> represents H, C(O)-CH<sub>2</sub>-NH<sub>2</sub>, or C(O)-CH(CH(CH<sub>3</sub>)<sub>2</sub>)-NH<sub>2</sub>;

R<sup>33</sup> and R<sup>34</sup> independently at each occurrence represent R<sup>10</sup>, (CH<sub>2</sub>)<sub>0-4</sub>-Ar, optionally substituted aryl, (CH<sub>2</sub>)<sub>0-4</sub> optionally substituted heteroaryl, (CH<sub>2</sub>)<sub>1-4</sub>-CN, (CH<sub>2</sub>)<sub>1-4</sub>-N(R<sup>10</sup>)<sub>2</sub>, (CH<sub>2</sub>)<sub>1-4</sub>-OH, (CH<sub>2</sub>)<sub>1-4</sub>-SO<sub>2</sub>-N(R<sup>10</sup>)<sub>2</sub>; alternatively;

R<sup>33</sup> and R<sup>34</sup> along with the nitrogen atom that they are attached form a 4 to 14 atom ring structure selected from tetrahydro-1H-carboline; 6,7-dialkoxyoxy-2-substituted 1,2,3,4-tetrahydro-isoquinoline,



R<sup>35</sup> represents R<sup>10</sup>, SO<sub>2</sub>-R<sup>10</sup>, COR<sup>10</sup>, or CONHR<sup>10</sup>;

E represents a bond, S(O)<sub>0-2</sub>, O or NR<sup>10</sup>;

W<sub>1</sub>, W<sub>2</sub>, W<sub>3</sub> and W<sub>4</sub> independently represent C or N; and




Q, Q<sup>1</sup>, Q<sup>2</sup>, Q<sup>3</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup> and L<sup>4</sup> independently at each occurrence represent N-natural or unnatural amino acid side chain, CHR<sup>10</sup>, O, NH, S(O)<sub>0-2</sub>, N-C(O)-NHR<sup>10</sup>, SO<sub>2</sub>-N(R<sup>10</sup>)<sub>2</sub>, N-C(O)-NH-(CH<sub>2</sub>)<sub>1-4</sub>-R<sup>26</sup>, NR<sup>10</sup>, N-heteroaryl, N-C(=NH)-NHR<sup>10</sup>, or N-C(=NH)C<sub>1-4</sub> alkyl;


R<sup>26</sup> represents OH, NH<sub>2</sub>, or SH;

provided that, (i) when R<sup>1</sup> = OH; R<sup>7</sup> = amidine; R<sup>2</sup>, R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>20</sup> each represent H; and R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> are independently chosen from H, CH<sub>3</sub>, and halogen, then only one of R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> represents H; (ii) when R<sup>1</sup> = OH; R<sup>7</sup> = amidine; R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>20</sup> each represent H; and R<sup>6</sup>, R<sup>8</sup>, R<sup>9</sup> are independently chosen from H, CH<sub>3</sub>, and halogen, then only one of R<sup>6</sup>, R<sup>8</sup>, and R<sup>9</sup> represents H; (iii) at least two of W<sub>1</sub>, W<sub>2</sub>, W<sub>3</sub> and W<sub>4</sub> represent C and at least one of W<sub>1</sub>, W<sub>2</sub>, W<sub>3</sub> and W<sub>4</sub> represent N; and (iv) when R<sup>1</sup> = OH; R<sup>7</sup> = amidine; and R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup>, and R<sup>9</sup>, represent H, R<sup>20</sup> cannot be CH<sub>3</sub>,[.] or a pharmaceutically acceptable salt thereof.

12. (Currently amended): A compound of Claim [2] 1 wherein A represents




B represents



X represents C; and  
Y represents NH.

13. (Currently amended): A compound of claim 12 wherein  
R<sup>1</sup> represents -OH, -COOH, or P(O)(OH)<sub>2</sub>;  
R<sup>2</sup> represents H, halogen, R<sup>10</sup>, -aryl, heteroaryl, -C<sub>1-2</sub>-alkyl, COOH, -OC<sub>1-2</sub>-alkyl, or -O-(CH<sub>2</sub>)<sub>0-2</sub>-aryl, or -C<sub>6-10</sub>-aryl-C<sub>1-4</sub>-alkyl;  
R<sup>3</sup> represents H or -O-(CH<sub>2</sub>)<sub>1-3</sub>-COOH;  
alternatively R<sup>2</sup> and R<sup>3</sup> taken together represent



- R<sup>4</sup> represents H, C<sub>1-4</sub> alkyl, -(CH<sub>2</sub>)<sub>1-4</sub>-COOH, -(CH<sub>2</sub>)<sub>1-4</sub>-COOC<sub>1-2</sub>-alkyl, halogen, -(CH<sub>2</sub>)<sub>1-2</sub>-CONH<sub>2</sub>, -CONH<sub>2</sub>, -NO<sub>2</sub>, -O-C<sub>1-2</sub> alkyl, or -OH;  
R<sup>5</sup> represents H, C<sub>1-3</sub> alkyl, ~~-(CH<sub>2</sub>)<sub>1-4</sub>-C(O)-NH-(CH<sub>2</sub>)<sub>1-3</sub>-heteroaryl, -(CH<sub>2</sub>)<sub>1-4</sub>-C(O)-NH-CH<sub>3</sub>,~~  
or -COOH;  
R<sup>6</sup> represents H, halogen, or -C<sub>1-3</sub> alkyl;  
R<sup>7</sup> represents -C(O)-NH<sub>2</sub>, -C(=NH)-NH-NH<sub>2</sub>, or amidino;  
R<sup>8</sup> represents H, or halogen; and  
R<sup>20</sup> represents H, -(CH<sub>2</sub>)<sub>1-4</sub>-Ph-N(SO<sub>2</sub>-C<sub>1-2</sub>alkyl), -(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-C(O)-R<sup>24</sup>, -(CH<sub>2</sub>)<sub>1-4</sub>-NR<sup>10</sup>-SO<sub>2</sub>-R<sup>24</sup>, -(CH<sub>2</sub>)<sub>1-4</sub>-het, -(CH<sub>2</sub>)<sub>1-4</sub>-CON(R<sup>10</sup>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>1-4</sub>-N(R<sup>10</sup>)-C(O)-NR<sup>10</sup>R<sup>24</sup>, ~~-(CH<sub>2</sub>)<sub>1-2</sub>-Ph-~~

$\text{NH}_2$ ,  $-(\text{CH}_2)_{1-2}$ - $\text{Ph}-\text{NO}_2$ ,  $-(\text{CH}_2)_{1-4}-\text{N}(\text{R}^{10})-\text{C}(\text{S})-\text{NR}^{10}\text{R}^{24}$ ,  $-\text{C}_{1-2}$ -alkyl,  $-(\text{CH}_2)_{1-4}$ -optionally substituted aryl,  $-(\text{CH}_2)_{1-4}$ -het;  $-(\text{CH}_2)_{1-3}-\text{N}(\text{R}^{10})_2$ ;  $-(\text{CH}_2)_{1-4}-\text{CON}(\text{R}^{10})_2$ , or  $-(\text{CH}_2)_{1-3}-\text{COOH}$ .

14. (Original) A compound of claim 13 wherein the compound is selected from  
3-Benzyl-2-(3-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid;  
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;  
6-Chloro-2-(3,5-dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-benzamide;  
2-(3,5-Dichloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
3-(4-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
2-(2-Hydroxy-biphenyl-3-yl)-1H-indole-5-carboxamidine;  
2-(3-Bromo-2-hydroxy-5-nitro-phenyl)-1H-indole-5-carboxamidine;  
2-(5-Hydroxy-2,3-dihydro-benzo[1,4]dioxin-6-yl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(3,5-difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(3,5-dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetic acid;  
3-Benzyl-2-(5-chloro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
2-[3-Bromo-5-(5-carbamimidoyl-1H-indol-2-yl)-4-hydroxy-phenyl]-acetamide;  
2-(3,5-Difluoro-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
2-(3,5-Dibromo-2-hydroxy-phenyl)-1H-indole-5-carboxamidine;  
2-(2-Hydroxy-5-methyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;  
2-(2-Hydroxy-5,4'-dimethyl-biphenyl-3-yl)-1H-indole-5-carboxamidine;  
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(2-hydroxy-3,5-dimethyl-phenyl)-1H-indole-5-carboxamidine;

Appl. No. 09/868,276  
Amdt. dated December 18, 2003  
Reply to Office Action of June 24, 2003

2-(3,5-Dibromo-2-hydroxy-phenyl)-3-methyl-1H-indole-5-carboxamidine;  
2-(2-Hydroxy-5-methyl-3-thiophen-2-yl-phenyl)-1H-indole-5-carboxamidine;  
2-[2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-5-carbamimidoyl-1H-indol-3-yl]-acetamide;  
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid methyl ester;  
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid methyl ester;  
3-(3-Amino-benzyl)-2-(3-bromo-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(3-nitro-benzyl)-1H-indole-5-carboxamidine;  
3-(3-Amino-benzyl)-2-(2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
3-Benzyl-2-(3-chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine;  
6-Chloro-2-{5-[2-(1,1-dioxo-1-thiomorpholin-4-yl)-2-oxo-ethyl]-2-hydroxy-biphenyl-3-yl}-1H-indole-5-carboxamidine;  
2-[5-(5-Carbamidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(2-piperidin-1-yl-ethyl)-acetamide;  
6-Chloro-2-{2-hydroxy-5-[2-(2-methoxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;  
6-Chloro-2-{2-hydroxy-5-[2-oxo-3-(tetrahydro-furan-2-yl)-propyl]-biphenyl-3-yl}-1H-indole-5-carboxamidine;  
2-[5-(5-Carbamidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(tetrahydro-furan-2-ylmethyl)-acetamide;  
2-[5-(5-Carbamidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yl]-N-(3-methoxy-propyl)-acetamide;  
Morpholine-4-carboxylic acid {2-[5-(5-carbamimidoyl-6-chloro-1H-indol-2-yl)-6-hydroxy-biphenyl-3-yloxy]-ethyl}-amide;  
Phosphoric acid mono-{2-[3-(3-benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-ethyl} ester;


Appl. No. 09/868,276  
Amdt. dated December 18, 2003  
Reply to Office Action of June 24, 2003

2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N-{4-[1-(1-imino-ethyl)-piperidin-4-yloxy]-phenyl}-acetamide;  
4-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-butyric acid;  
2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetamide;  
2-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-N,N-dimethyl-acetamide;  
[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-acetic acid;  
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-pentanedioic acid bis-[(2-morpholin-4-yl-ethyl)-amide];  
3-[3-(3-Benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionamide;  
and  
2-(3-Bromo-2-hydroxy-5-methyl-phenyl)-3-(4-nitro-benzyl)-1H-indole-5-carboxamidine;  
or a stereoisomer or pharmaceutically acceptable salt form thereof.


15. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof.

Appl. No. 09/868,276  
Amdt. dated December 18, 2003  
Reply to Office Action of June 24, 2003

16. (Currently amended): [A] ~~The method of Claim 11 for treating or preventing a thromboembolic disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 12 or a pharmaceutically acceptable salt thereof~~ wherein A represents



B represents



X represents C; and

Y represents NH.